These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31248654)

  • 41. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.
    Quispe R; Martin SS; Michos ED; Lamba I; Blumenthal RS; Saeed A; Lima J; Puri R; Nomura S; Tsai M; Wilkins J; Ballantyne CM; Nicholls S; Jones SR; Elshazly MB
    Eur Heart J; 2021 Nov; 42(42):4324-4332. PubMed ID: 34293083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trends in lipid profiles and descriptive characteristics of U.S. adults with and without diabetes and cholesterol-lowering medication use-National Health and Nutrition Examination Survey, 2003-2012, United States.
    Mercado CI; Gregg E; Gillespie C; Loustalot F
    PLoS One; 2018; 13(3):e0193756. PubMed ID: 29509776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults.
    Zhang M; Deng Q; Wang L; Huang Z; Zhou M; Li Y; Zhao Z; Zhang Y; Wang L
    Int J Cardiol; 2018 Jun; 260():196-203. PubMed ID: 29622441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
    N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
    Packard CJ
    Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys.
    Patel KK; Taksler GB; Hu B; Rothberg MB
    Ann Intern Med; 2017 Jun; 166(12):876-882. PubMed ID: 28505660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
    Howard WJ
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey.
    Hickman TB; Briefel RR; Carroll MD; Rifkind BM; Cleeman JI; Maurer KR; Johnson CL
    Prev Med; 1998; 27(6):879-90. PubMed ID: 9922071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults.
    Kilgore M; Muntner P; Woolley JM; Sharma P; Bittner V; Rosenson RS
    J Clin Lipidol; 2014; 8(1):86-93. PubMed ID: 24528689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
    Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
    Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between low-density and non-high-density lipoprotein cholesterol with incident cardiovascular disease among low-risk Iranians during 2 decades follow-up.
    Tohidi M; Asgari S; Chary A; Azizi F; Hadaegh F
    Clin Biochem; 2022; 109-110():28-36. PubMed ID: 35970222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.